Abraham Kanate, MD
Hematology & Oncology · Morgantown, WVNPI 1962600965
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $145,580 of the $169,412 with a category attached, or 85.9%. 26 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 53.1% of the total. 2025 is the largest year on record at $115,843, more than ten times the $105 reported in 2019. Among hematology & oncology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $743.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$90K
- Gilead$32K
- Johnson & Johnson$20K
- ADC Therapeutics America, Inc.$19K
- AbbVie$4K
- Janssen Scientific Affairs, LLC$1K
- plus $3K from 20 others
Across 96 payments — averaging $6935.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$143K
- Institut DE Recherches Servier$97K
- Merck$72K
- Genentech, Inc.$68K
- Acerta Pharma LLC$64K
- Bristol Myers Squibb$62K
- plus $160K from 7 others
What the payments were for
- Consulting fees$7,4164%
- Speaking & faculty fees$145,58086%
- Travel & lodging$10,6346%
- Food & beverage$5,6293%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 41 | $89,941 |
| Gilead(2 entities) | 38 | $32,266 |
| Johnson & Johnson | 27 | $20,213 |
| ADC Therapeutics America, Inc. | 17 | $18,625 |
| AbbVie | 14 | $4,377 |
| Janssen Scientific Affairs, LLC | 1 | $1,150 |
| Bristol Myers Squibb | 12 | $696 |
| Jazz Pharmaceuticals Inc. | 9 | $253 |
| Incyte Corporation | 7 | $241 |
| Sanofi | 2 | $201 |
| Astellas Pharma US Inc | 6 | $175 |
| Pfizer | 7 | $160 |
| Servier Pharmaceuticals LLC | 7 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $139 |
| Genmab U.S., Inc. | 4 | $126 |
| Sanofi-aventis U.S. LLC | 4 | $119 |
| Novartis | 6 | $111 |
| Seagen Inc. | 3 | $91 |
| Syndax Pharmaceuticals, Inc. | 3 | $85 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Acrotech Biopharma Inc. | 4 | $54 |
| Rigel Pharmaceuticals, Inc. | 2 | $54 |
| Genentech USA, Inc. | 2 | $40 |
| Legend Biotech USA Inc. | 1 | $28 |
| Amgen | 1 | $25 |
| Merck | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$169,412 in reported general payments places this provider in the 95th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 24 | $441,048 |
| PromactaEltrombopag Olamine | 16 | $251,763 |
| ImbruvicaIbrutinib | 13 | $70,725 |
| VenclextaVenetoclax | 13 | $36,985 |
| EliquisApixaban | 11 | $8,798 |
| ValacyclovirValacyclovir Hcl | 24 | $1,074 |
| Acyclovir | 92 | $916 |
| Fluconazole | 21 | $436 |
| Sirolimus | 11 | $408 |
| Ursodiol | 11 | $389 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 49 | $221 |
| Montelukast Sodium | 21 | $205 |
| Levetiracetam | 11 | $176 |
| Pantoprazole Sodium | 22 | $162 |
| Prednisone | 29 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $241 | $441,04824 claims |
| NovartisPromacta | $111 | $251,76316 claims |
| AbbVieVenclexta | $4,377 | $36,98513 claims |
| PfizerEliquis | $160 | $8,79811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Morgantown
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Ihtishaam QaziMorgantown$18K
- Sonikpreet AulakhMorgantown$17K
- Salah Ud Din SafiMorgantown$5K
- Michael CraigMorgantown$5K
- Joanna KolodneyMorgantown$3K
- Amir KamranMorgantown$2K
- Sobha KurianMorgantown$1K
- Pooja Gogia BhasinMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.